No, You Should Not Abruptly Stop Metoprolol
Beta-blockers like metoprolol should not be stopped suddenly unless absolutely necessary, as there is a significant risk of rebound myocardial ischemia, myocardial infarction, ventricular arrhythmias, and even death 1, 2. This warning applies across multiple clinical contexts including heart failure, coronary artery disease, and hypertension.
Why Abrupt Discontinuation Is Dangerous
The FDA drug label explicitly warns against abrupt discontinuation in patients with coronary artery disease, stating that severe exacerbation of angina, myocardial infarction, and ventricular arrhythmias have been reported 2. The 2012 ESC Heart Failure Guidelines emphasize that beta-blockers should not be stopped suddenly unless absolutely necessary, noting the risk of rebound increase in myocardial ischemia or infarction and arrhythmias 1.
The physiologic mechanism involves beta-adrenergic receptor upregulation during chronic therapy. Research demonstrates that abrupt metoprolol withdrawal causes a 52% rebound increase in cardiac chronotropic sensitivity to isoproterenol and a 15% rebound rise in resting heart rate within 2-8 days 3. Heart rate variability studies show that withdrawal shifts autonomic balance toward lower vagal and higher sympathetic tone within just 24 hours 4.
Clinical Evidence of Harm
In patients with dilated cardiomyopathy receiving long-term metoprolol, withdrawal led to deterioration in 7 of 13 patients, including 4 deaths (sudden cardiac death or heart failure) during the 4-month period after cessation 5. This underscores that in patients where beta-blocker therapy is effective, withdrawal can be fatal.
Perioperative studies show that beta-blocker withdrawal increases mortality risk. One study found 50% mortality in patients who had beta-blockers discontinued postoperatively versus 1.5% in those who continued (OR 65.0) 6. Another demonstrated that withdrawal was associated with increased 1-year mortality (HR 2.7) compared to nonusers 6.
How to Safely Discontinue When Necessary
When discontinuation is required, the dose should be gradually reduced over 1-2 weeks with careful patient monitoring 2. The ACC/AHA guidelines consistently recommend avoiding abrupt cessation across multiple contexts 7, 8, 9.
Tapering Protocol:
- Reduce dose gradually over 1-2 weeks minimum
- Monitor closely for angina, arrhythmias, or heart failure symptoms
- If angina worsens or acute coronary insufficiency develops, reinstate metoprolol immediately 2
- Consider using short-acting formulations during taper for better control
Research comparing abrupt versus tapered withdrawal found that prolonged low-dose withdrawal (50 mg/day for 10 days) decreased but did not completely prevent rebound phenomena 3. This suggests even gradual tapering carries some risk, reinforcing the need for close monitoring.
Special Populations and Exceptions
In patients with thyrotoxicosis, abrupt withdrawal may precipitate thyroid storm 2. In pheochromocytoma, beta-blockers should only be used with alpha-blockade, and withdrawal requires extreme caution 2.
The 2009 ACC/AHA perioperative guidelines note that chronically administered beta-blocker therapy should not be routinely withdrawn prior to major surgery, and continuation is a Class I indication 6.
Important Caveat: Recent Evidence in Stable Post-MI Patients
Recent 2026 data from the SMART-DECISION trial and pooled analysis suggest that in highly selected stable patients (>1 year post-MI, LVEF ≥40%, no heart failure, no other indication), discontinuation may be non-inferior to continuation 10, 11. However, these patients represent a narrow subset, and discontinuation was still performed in a controlled research setting with close monitoring—not abruptly.
Bottom Line
Warn patients explicitly against interrupting or discontinuing therapy without physician guidance 2. Even in patients treated only for hypertension, it may be prudent not to discontinue abruptly, as coronary artery disease may be unrecognized 2. The risk-benefit calculation overwhelmingly favors gradual tapering over abrupt cessation in virtually all clinical scenarios.